Current Gastroenterology Reports

, Volume 8, Issue 4, pp 305–311

Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth

Article

Abstract

Irritable bowel syndrome (IBS) is a complex, yet common diagnosis in gastroenterology. Recent data suggest the increasing importance of bacteria in the pathophysiology of IBS. Some studies have shown that IBS can be precipitated by an acute case of gastroenteritis. These pathogenic organisms may contribute to long-term gut dysfunction. In another line of effort, a growing body of evidence links IBS to the presence of excessive bacteria in the small bowel, called bacterial overgrowth. Although the means by which this is determined have been indirect, studies demonstrating the benefit of unabsorbed antibiotics suggest that reduction in gut flora is important. Further work has also examined bacterial overgrowth in the context of the various symptoms of patients with IBS. These symptom complexes include constipation, diarrhea, and alternating forms of the condition. Although this idea seems initially counterintuitive, it has been demonstrated that the fermentation of methane in the gut is associated with and can result in the slowing of intestinal transit, resulting in constipation. In this review, these topics are discussed and outlined.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Drossman DA, Sandler RS, McKee DL, et al.: Bowel patterns among subjects not seeking health care. Gastroenterology 1982, 83:529–534.PubMedGoogle Scholar
  2. 2.
    Thompson WG, Heaton KW: Functional bowel disorders in apparently healthy people. Gastroenterology 1980, 79:283–288.PubMedGoogle Scholar
  3. 3.
    Thompson WG: The functional gastrointestinal bowel disorders. In The Functional Gastrointestinal Disorders. Edited by Drossman DA. Boston: Little, Brown; 1994:117–134.Google Scholar
  4. 4.
    Drossman DA: Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 1999, 107:41S-50S.PubMedCrossRefGoogle Scholar
  5. 5.
    Ritchie J: Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973, 14:125–132.PubMedGoogle Scholar
  6. 6.
    Prior A, Maxton DG, Whorwell PJ: Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990, 31:458–462.PubMedGoogle Scholar
  7. 7.
    Richter JE, Barish CF, Castell DO: Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology 1986, 91:845–852.PubMedGoogle Scholar
  8. 8.
    Whitehead WE, Holtkotter B, Enck P, et al.: Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990, 98:1187–1192.PubMedGoogle Scholar
  9. 9.
    Bradette M, Pare P, Douville P, et al.: Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig Dis Sci 1991, 36:52–58.PubMedCrossRefGoogle Scholar
  10. 10.
    Lemann M, Dederding JP, Flourie B, et al.: Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome. Dig Dis Sci 1991, 36:1249–1254.PubMedCrossRefGoogle Scholar
  11. 11.
    Mearin F, Cucala M, Azpiroz F, et al.: The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991, 101:999–1006.PubMedGoogle Scholar
  12. 12.
    Mayer EA, Gebhart GF: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994, 107:271–293.PubMedGoogle Scholar
  13. 13.
    Mertz H, Nabiloff B, Munakata J, et al.: Altered rectal perception is a biological marker of patients with the irritable bowel syndrome. Gastroenterology 1995, 109:40–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Nabiloff BD, Mayer EA: Sensational developments in irritable bowel syndrome. Gut 1996, 39:770–771.Google Scholar
  15. 15.
    Munakata J, Nabiloff B, Harraf F, et al.: Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997, 112:55–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Lembo T, Munakata J, Nabiloff B, et al.: Sigmoid afferent mechanisms in patients with irritable bowel syndrome. Dig Dis Sci 1997, 42:1112–1120.PubMedCrossRefGoogle Scholar
  17. 17.
    Harraf F, Schmulson M, Saba L, et al.: Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut 1998, 43:388–394.PubMedCrossRefGoogle Scholar
  18. 18.
    Whitehead WE, Palsson OS: Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception. Gastoenterology 1998, 115:1263–1271.CrossRefGoogle Scholar
  19. 19.
    Chun A, Desautels S, Slivka A, et al.: Visceral algesia in irritable bowel syndrome fibromyalgia, and sphincter of Oddi dysfuntion, type III. Dig Dis Sci 1999, 44:631–636.PubMedCrossRefGoogle Scholar
  20. 20.
    O’Brien MD, Phillips SF: Colonic motility in health and disease. Gastroenterol Clin North Am 1996, 25:147–162.PubMedCrossRefGoogle Scholar
  21. 21.
    McKee DP, Quigley FM: Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci 1993, 38:1761–1772.PubMedCrossRefGoogle Scholar
  22. 22.
    McKee DP, Quigley FM: Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci 1993, 38:1773–1782.PubMedCrossRefGoogle Scholar
  23. 23.
    Lind CD: Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 1991, 20:279–295.PubMedGoogle Scholar
  24. 24.
    Drossman DA, Li Z, Andruzzi E, et al.: U.S. householder study on functional gastrointestinal disorders Prevalence, sociodemography and health impact. Dig Dis Sci 1993, 38:1569–1580.PubMedCrossRefGoogle Scholar
  25. 25.
    Halpert A, Dalton CB, Diamant NE, et al.: Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005 Mar, 100:664–671.PubMedCrossRefGoogle Scholar
  26. 26.
    Tabas G, Beaves M, Wang J, et al.: Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004, 99:914–920.PubMedCrossRefGoogle Scholar
  27. 27.
    Patrick DL, Drossman DA, Frederick IO, et al.: Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998, 43:400–411.PubMedCrossRefGoogle Scholar
  28. 28.
    Talley NJ: Antidepressants in IBS: Are we deluding ourselves? Am J Gastroenterol 2004, 99:921–923.PubMedCrossRefGoogle Scholar
  29. 29.
    Neal KR, Hebden J, Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis, and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997, 314:779–782.PubMedGoogle Scholar
  30. 30.
    Parry SD, Stansfield R, Jelley D, et al.: Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol 2003, 98:238–241.CrossRefGoogle Scholar
  31. 31.
    Neal KR, Barker L, Spiller RC: Prognosis in post-infectious irritable bowel syndrome: a six year follow up study. Gut 2002, 51:410–413.PubMedCrossRefGoogle Scholar
  32. 32.
    Barber R, Blakey A: Prevalence of gastrointestinal symptoms after bacterial gastroenteritis: study did not include control group. BMJ 1997, 314:1903.PubMedGoogle Scholar
  33. 33.
    Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804–811.PubMedCrossRefGoogle Scholar
  34. 34.
    Dunlop SP, Jenkins D, Neal KR, et al.: Randomized, double-blind, placebo-controlled trial of prednisolone in postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:77–84.PubMedCrossRefGoogle Scholar
  35. 35.
    O’Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541–551.PubMedCrossRefGoogle Scholar
  36. 36.
    Lewis MJ, Reilly B, Houghton LA, Whorwell PJ: Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut. 2001, 48:216–220.PubMedCrossRefGoogle Scholar
  37. 37.
    King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998, 352:1187–1189.PubMedCrossRefGoogle Scholar
  38. 38.
    Koide A, Yamaguchi T, Odaka T, et al.: Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1735–1741.PubMedCrossRefGoogle Scholar
  39. 39.
    Salvioli B, Serra J, Azpiroz F, et al.: Origin of gas retention and symptoms in patients with bloating. Gastroenterology 2005, 128:574–579.PubMedCrossRefGoogle Scholar
  40. 40.
    Pimentel M, Soffer EE, Chow EJ, et al.: Low frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002, 47:2639–2643.PubMedCrossRefGoogle Scholar
  41. 41.
    Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503–3506.PubMedCrossRefGoogle Scholar
  42. 42.
    Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double blind randomized, placebo controlled study. Am J Gastroenterol 2003, 98:412–419.PubMedGoogle Scholar
  43. 43.
    Galatola G, Grosso M, Barlotta A, et al.: Diagnosis of bacterial contamination of the small intestine using the 1 g [14C] xylose breath test in various gastrointestinal diseases. Minerva Gastroenterol Dietol 1991, 37:169–175.PubMedGoogle Scholar
  44. 44.
    Nucera G, Gabriella M, Lupascu A, et al.: Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005, 21:1391–1395.PubMedCrossRefGoogle Scholar
  45. 45.
    Lupascu A, Gabrielli M, Lauritano EC, et al.: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005, 22:1157–1160.PubMedCrossRefGoogle Scholar
  46. 46.
    McCallum R, Schultz C, Sostarich S: Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT). Gastroenterol 2005, 128:A460.Google Scholar
  47. 47.
    Walters B, Vanner SJ: Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005, 100:1566–1570.PubMedCrossRefGoogle Scholar
  48. 48.
    Simren M, Ringstorm G, Agerforz P, et al.: Small intestinal bacterial overgrowth is not of major importance in irritable bowel syndrome, Gastroenterology 2003, 124:A163.CrossRefGoogle Scholar
  49. 49.
    Robson KM, Kakullavarapu J, Lembo T: Bacterial overgrowth and irritable bowel syndrome: a look at prevalence: symptoms and quality of life. Am J Gastroenterol 2003, 98:S271.CrossRefGoogle Scholar
  50. 50.
    ROME II: The Functional Gastrointestinal Disorders, edn 2. McLean, VA: Management Services, Degnon Associates; 2006.Google Scholar
  51. 51.
    Pimentel M, Mayer AG, Park S, et al.: Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 2003, 48:86–92. This reference represents the first large-scale description of the association of methane with constipation symptoms among IBS subjects. Among subjects who only produced methane on breath test, all had constipation-predominant IBS. The study also included a group of inflammatory bowel disease patients. In that group the prevalence of methane was negligible.PubMedCrossRefGoogle Scholar
  52. 52.
    Fiedorek SC, Pumphrey CL, Casteel HB: Breath methane production in children with constipation and encoparesis. J Pediatr Gastroenterol 1990, 10:473–477.CrossRefGoogle Scholar
  53. 53.
    Fiedorek SC, Pumphrey CL, Casteel HB: Breath methane production in children with constipation and encoparesis. J Pediatr Gastroenterol 1990, 10:473–477.CrossRefGoogle Scholar
  54. 54.
    Pimentel M, Lin HC, Enayati P, et al.: Methane, a gas produced by enteric bacteria, slows intestinal transit and augments ileal contractile activity. Am J Physiol S Gastrointest Liver Physiol 2006, 290:G1089-G1095.CrossRefGoogle Scholar
  55. 55.
    Cloarec D, Bornet F, Gouilloud S, et al.: Breath hydrogen response to lactulose in healthy subjects: relationship to methane producing status. Gut 1990, 31:300–304.PubMedGoogle Scholar
  56. 56.
    Stephan AM, Wiggins HS, Englyst HN, et al.: The effect of age, sex and level of dietary fiber from wheat on largebowel function in thirty healthy subjects. Br J Nutr 1986, 56:349–361.CrossRefGoogle Scholar
  57. 57.
    Soares AC, Lederman HM, Fagundes-Neto U, et al.: Breath methane associated with slow colonic transit time in children with chronic constipation. J Clin Gastroenterol 2005, 39:512–515.PubMedCrossRefGoogle Scholar
  58. 58.
    Vantrappen G, Janssens J, Hellemans J, Ghoos Y: The interdigestive Motor complex of normal subjects with bacterial overgrowth of the small intestine. J Clin Invest 1977, 59:1158–1166.PubMedCrossRefGoogle Scholar
  59. 59.
    Szurszewski JH: A migrating electric complex of the canine small intestine. Am J Physiol 1969, 217:1757–1763.PubMedGoogle Scholar
  60. 60.
    Pimentel M, Soffer EE, Chow EJ, Lin HC: Lower frequency of MMC is found in IBS subjects with abnormal breath test suggesting bacterial overgrowth. Dig Dis Sci 2002, 47:2639–2643.PubMedCrossRefGoogle Scholar
  61. 61.
    Bjornsson ES, Abrahamsson H: Comparison between physiologic and erythromycin-induced interdigestive motility. Scand J Gastroenterol 1995, 30:139–145.PubMedGoogle Scholar
  62. 62.
    Attar A, Fluorie B, Rambaud JC, et al.: Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999, 117:794–797.PubMedCrossRefGoogle Scholar
  63. 63.
    Di Stefano M, Malservisi S, Veneto G, et al.: Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000, 14:551–556.CrossRefGoogle Scholar
  64. 64.
    Sharara AI, Aoun E, Abdul-Baki H, et al.: A randomized double blind placebo controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006, 101:326–333.PubMedCrossRefGoogle Scholar
  65. 65.
    Pimentel M, Park S, Kong Y, Kane SV: Rifaximin, a nonabsorbable antibiotic improves the symptoms of irritable bowel syndrome: A double-blind randomized controlled study. Am J Gastroenterol 2005, 100:S324.Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.GI Motility LaboratoryCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations